Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
Authors: Isobe, Y.; Sugimoto, K.; Masuda, A.; Hamano, Y.; Oshimi, K.
Source: Internal Medicine Journal, Volume 39, Number 6, June 2009 , pp. 408-411(4)
Imatinib mesylate (IM) is currently used as the first therapeutic choice against chronic myelogenous leukaemia (CML). Because IM poorly penetrates the blood-brain barrier, IM-treated CML patients may have a potential risk of central nervous system (CNS) involvement. Here we report a case with lymphoid blast crisis isolated only in CNS after bacterial meningitis, although the patient achieved and maintained complete cytogenetic response by IM therapy. It is important to consider isolated CNS blast crisis as a possible event in IM-treated CML patients.
Document Type: Research Article
Publication date: June 2009